Vapotherm

Vapotherm's HVT 2.0 System Overcomes Regulatory Hurdles for Entry into South America's Largest Health Care Market

Retrieved on: 
Thursday, February 29, 2024
VAPO, Intensive care medicine, Social media, Hospital, Compressed air, USD, Ageing, Periodic breathing, HVT, Vapotherm, Health, Patient, Optimism, OTCQX, COPD, Pharmaceutical industry

With the approval and subsequent launch of HVT 2.0 in Brazil, we look forward to establishing ourselves as a frontline solution in Latin America."

Key Points: 
  • With the approval and subsequent launch of HVT 2.0 in Brazil, we look forward to establishing ourselves as a frontline solution in Latin America."
  • These features facilitate optimal patient care in the most advanced hospitals as well as resource constrained environments.
  • With the approval of the new system in Brazil, Vapotherm is launching a new Portuguese website and social media campaign.
  • The Company attended in the XXVIII Brazilian Congress of Intensive Care Medicine, the largest event of its kind in Latin America, to collaborate with approximately three thousand clinicians.

OTC Markets Group Welcomes Vapotherm, Inc. to OTCQX

Retrieved on: 
Friday, December 15, 2023
OTCQX, Periodic breathing, Vapotherm, Patient, VAPO, Security (finance)

NEW YORK, Dec. 15, 2023 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for 12,000 U.S. and international securities, today announced Vapotherm, Inc. (OTCQX: VAPO), a global medical technology company specializing in the development and commercialization of its proprietary Vapotherm high-velocity therapy® products for patients of all ages experiencing respiratory distress, has qualified to trade on the OTCQX® Best Market.

Key Points: 
  • NEW YORK, Dec. 15, 2023 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for 12,000 U.S. and international securities, today announced Vapotherm, Inc. (OTCQX: VAPO), a global medical technology company specializing in the development and commercialization of its proprietary Vapotherm high-velocity therapy® products for patients of all ages experiencing respiratory distress, has qualified to trade on the OTCQX® Best Market.
  • Vapotherm, Inc. voluntarily transferred to OTCQX from the New York Stock Exchange.
  • Trading on the OTCQX Market offers companies efficient, cost-effective access to the U.S. capital markets.
  • To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws.

Generations at Regency Joins Elite Healthcare Facilities Achieving Improved Patient Safety and Quality of Patient Care

Retrieved on: 
Friday, December 22, 2023
Rehabilitation, Friends, Long-term care, Patient safety, RRT, Accreditation, Health, AARC, Enhanced, Generation, Vapotherm, Letter, American College, Patient, Safety, Former, Nursing

NILES, Ill., Dec. 22, 2023 /PRNewswire-PRWeb/ -- The Physician-Patient Alliance for Health & Safety (PPAHS) is pleased to announce that Generations at Regency in Niles, Illinois, is one of the first healthcare facilities in Illinois and in the mid-west to achieve Enhanced Respiratory Care Accreditation.

Key Points: 
  • Enhanced Respiratory Care Accreditation demonstrates our continuing commitment to providing exceptional patient care.
  • "Generations at Regency offers a family-like setting for seniors needing long-term care or short-term rehabilitation," said Renee Ramos (Administrator, Generations at Regency).
  • Healthcare facilities looking to demonstrate their commitment to patient safety and the quality of patient care are invited to complete the online form to apply for Enhanced Respiratory Care Accreditation.
  • PPAHS would like to thank Breas, Fisher & Paykel Healthcare, and Vapotherm for sharing our goal to improve patient safety and the quality of patient care and for their educational support of the Enhanced Respiratory Care Program.

Generations at Oakton Pavillion Joins Top 1% Healthcare Facilities Achieving Improved Patient Safety and Quality of Patient Care

Retrieved on: 
Friday, December 15, 2023
Safety, AARC, Frontier Nursing Service, RRT, Accreditation, Patient, Former, Enhanced, American College, Generation, Letter, Vapotherm, Health, Hospital, Nursing, JD

DES PLAINES, Ill., Dec. 15, 2023 /PRNewswire-PRWeb/ -- The Physician-Patient Alliance for Health & Safety (PPAHS) is pleased to announce that Generations at Oakton Pavillion in Des Plaines, Illinois, is the first healthcare facility in Illinois and in the mid-west to achieve Enhanced Respiratory Care Accreditation.

Key Points: 
  • Generations at Oakton Pavillion is in the top 1% of the long-term care facilities ... families will know that their loved ones when cared for at Generations at Oakton Pavillion are receiving a quality of care that is following the highest national standard of care.
  • "Generations at Oakton Pavillion has met or exceeded the Enhanced Respiratory Care Standards set by the Enhanced Respiratory Care Committee," said Michael Wong, JD (Founder and Executive Director, Physician-Patient Alliance for Health & Safety).
  • "By receiving Enhanced Respiratory Care Accreditation, this means that Generations at Oakton Pavillion is in the top 1% of the long-term care facilities.
  • Healthcare facilities looking to demonstrate their commitment to patient safety and the quality of patient care are invited to complete the online form to apply for Enhanced Respiratory Care Accreditation.

Vapotherm Announces Suspension of NYSE Listing Common Stock Expected to Begin Trading Promptly on OTCQX

Retrieved on: 
Thursday, December 14, 2023
Shareholder, NYSE, OTC Markets Group, OTCQX, Patient, VAPO, Cryptocurrency, Vapotherm

EXETER, N.H., Dec. 14, 2023 /PRNewswire/ -- Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company") today announced it has received notice that the New York Stock Exchange ("NYSE") has determined to suspend trading of – and commence proceedings to delist – shares of the Company's common stock, effective immediately.

Key Points: 
  • EXETER, N.H., Dec. 14, 2023 /PRNewswire/ -- Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company") today announced it has received notice that the New York Stock Exchange ("NYSE") has determined to suspend trading of – and commence proceedings to delist – shares of the Company's common stock, effective immediately.
  • Vapotherm anticipates that its common stock will begin trading on the OTCQX Market ("OTCQX"), the highest market tier operated by OTC Markets Group, Inc. on December 15, 2023 under its current symbol VAPO.
  • Investors are expected to continue to be able to access accurate information, including stock price quotes, and execute trades.
  • Stockholders will not be required to exchange any shares, and the Company expects electronic trading to be available without any material disruption.

Vapotherm Educates over 8,000 Clinicians in Respiratory Care Month

Retrieved on: 
Tuesday, November 28, 2023
Respiratory Care Week, VAPO, HVT, Hospital, NYSE, Patient, Vapotherm, Health, Education, Nursing

The education was free to clincians in celebration of Respiratory Care Week, and continued through the month of October culminating in the American Association for Respiratory Care Congress 5-8 November.

Key Points: 
  • The education was free to clincians in celebration of Respiratory Care Week, and continued through the month of October culminating in the American Association for Respiratory Care Congress 5-8 November.
  • Dr. Jessica Whittle, Chief Medical Officer at Vapotherm, shared her enthusiasm: "About 7,000 clinicians initially registered for our educational programs, and we are thrilled that even more participated as the value became more well-known.
  • Vapotherm is committed to partnering with clinicans to provide the highest level of patient care.
  • Dr. Whittle and Joe Army were both present at the American Association for Respiratory Care Congress to celebrate this accomplishment and educate about the HVT 2.0 system.

Vapotherm To Report Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, November 1, 2023
VAPO, Telephone, Security (finance), NYSE, Regulation Fair Disclosure, Regulation, Cryptocurrency, Vapotherm

EXETER, N.H., Nov. 1, 2023 /PRNewswire/ -- Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), today announced that it will release financial results for the third quarter of 2023 after the close of trading on Wednesday, November 8, 2023.

Key Points: 
  • EXETER, N.H., Nov. 1, 2023 /PRNewswire/ -- Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), today announced that it will release financial results for the third quarter of 2023 after the close of trading on Wednesday, November 8, 2023.
  • ET to discuss the financial results and recent business developments.
  • To listen to a live webcast, please visit the Investors section of the Vapotherm website at: http://investors.vapotherm.com/events-and-presentations/events .
  • The webcast replay will be available on the Vapotherm website for 12 months following completion of the call.

Computational Fluid Dynamics (CFD) modeling further distinguishes Vapotherm High Velocity Therapy from generic high flow cannulas

Retrieved on: 
Wednesday, October 4, 2023
Medical Supplies, Health, Medical Devices, Managed Care, Clinical Trials, Pharmaceutical, Biotechnology, COPD, Oxygen, Asthma, Engineering, Turbulence, VAPO, Ventilation, Chronic obstructive pulmonary disease, NYSE, Journal, Patient, Periodic breathing, Conference, CO2, Medical imaging, Vapotherm

Computational fluid dynamics uses advanced computer algorithms to understand gas flow characteristics in changing and complex systems.

Key Points: 
  • Computational fluid dynamics uses advanced computer algorithms to understand gas flow characteristics in changing and complex systems.
  • Vapotherm’s unique small bore design generates higher gas velocity distinguishing it from other forms of high flow cannulas.
  • The modeling confirmed that the higher velocity generated by the Vapotherm design results in improved CO2 flush compared to other cannulas.
  • ( https://dl.astfe.org/conferences/tfec2023,1ee0374044f80bd3,2fec083b2a0b5... )
    “This reaffirms that not all high flow devices are the same and shows the value of high velocity therapy for clearance of CO2 and flush of the upper airway,” said Brian Lawrence, Chief Technology Officer at Vapotherm.

The FDA Approves IDE for ReGelTec’s Pivotal Study of HYDRAFIL® for Chronic Low Back Pain due to Degenerative Disc Disease

Retrieved on: 
Thursday, September 28, 2023
FDA, Health, Surgery, Medical Devices, Low back pain, Degenerative disc disease, VAPO, Hydrogel, Comprehensive, Oswestry Disability Index, Patient, Clinical research, IDE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NYSE, Food, Safety, Pharmaceutical industry, Vapotherm

ReGelTec, Inc. , announced that the U.S. Food and Drug Administration has approved an IDE for the company’s pivotal study to support premarket approval of its HYDRAFIL® System.

Key Points: 
  • ReGelTec, Inc. , announced that the U.S. Food and Drug Administration has approved an IDE for the company’s pivotal study to support premarket approval of its HYDRAFIL® System.
  • The HYDRAFIL System contains an injectable polymer that is implanted percutaneously via a needle to augment the native disc in a procedure performed under local anesthesia at an outpatient surgery center.
  • The HYDRogel Augmentation For Intervertebral Lumbar Discs (HYDRAFIL-D) Study , is a multicenter, single-blinded, randomized, controlled trial to evaluate the safety and efficacy of the HYDRAFIL System for treatment of chronic low back pain due to degenerative disc disease.
  • The HYDRAFIL-D Study will enroll approximately 225 patients in up to fifteen centers across North America and is expected to start in early 2024 after the company completes its next round of financing.

Pilot Study demonstrates Vapotherm HVNI technology is more effective than standard oxygen therapy for treatment of acute asthma in children

Retrieved on: 
Monday, September 25, 2023
Medical Devices, Health, Managed Care, Clinical Trials, Pharmaceutical, Biotechnology, Asthma, University Hospitals Cleveland Medical Center, VAPO, Emergency department, CDC, Patient, Child, Asthma and Allergy Foundation of America, NHS, Periodic breathing, NYSE, Pharmaceutical industry, Vapotherm, DRS

The study was conducted through the Brighton and Sussex Clinical Trial Unit at University Hospitals, Sussex, England under the direction of Drs.

Key Points: 
  • The study was conducted through the Brighton and Sussex Clinical Trial Unit at University Hospitals, Sussex, England under the direction of Drs.
  • Children who presented to the Emergency Department with acute, severe, asthma exacerbations that did not respond to initial pharmacologic treatment were randomized to either HVNI or standard nasal oxygen therapy.
  • Eighty-six percent (19/22) of children treated with standard oxygen required escalation of therapy, while only 61% (17/28) of children treated with HVNI needed further escalation.
  • Almost 5 million children in the USA, and 1 million children in the UK have asthma, according to the CDC and NHS.